The Future of Innovative Medicine Pricing and Reimbursement in China: Signals from the 2024 NRDL Negotiations
These developments call for a global pricing strategy rooted in China's evolving reimbursement infrastructure, breaking siloed thinking to balance short-term goals with long-term growth.
China's Commercial Health Insurance Formulary Development: Current State and Future Directions
Executive Summary
The commercial health insurance sector in China presents substantial opportunities for growth, with the development of commercial insurance
Fostering Medical Innovation: How China's Social and Commercial Insurance Can Work Together
A healthy innovation ecosystem for medicines in China requires effective integration between basic and commercial health insurance. Success hinges on stakeholders operating within China's social security framework and focusing first on tackling the low-hanging fruit.
Impacts of Provincial Central Pooling of Basic Medical Insurance on China's Healthcare Ecosystem
Increasing the risk pooling level is essential for reducing regional disparities and improving the efficiency of BMI funds. This change will deeply affect the supply and demand sides of China's healthcare ecosystem.
Advancements in China's BMI Payment Policies for High-Value Medical Consumables: How MedTech Should Prepare
These policies create a national framework for the pricing and reimbursement of high-value medical consumables under basic medical insurance schemes, necessitating proactive preparedness from MedTech firms.
Quantifying Innovation: Three Key Signals from NHSA's Draft on New Chemical Drug Launch Pricing
The standout enhancement in the current proposal is the addition of a self-assessment scale. This tool, designed to assign a score that quantifies innovation quality based on the company's self-assessment, plays a crucial role in determining the initial pricing of their drugs.
